Sign In
Buy GLP
$48.45
-0.81 (-1.64%)
At Close: Jun 03, 2026
GLP: Attractive Yield And Business If Traditional Energy Production Increases
01:06pm, Tuesday, 30'th Jul 2024
The 2024 U.S. election will impact oil and gasoline prices, affecting economic conditions and inflation. Global Partners LP focuses on traditional hydrocarbons, but has initiatives for low carbon solu
GLP-1s, Surging Medical Costs Have Employers Taking a Hard Look at the Return on Investment
09:00am, Tuesday, 30'th Jul 2024
ROLLING MEADOWS, Ill. , July 30, 2024 /PRNewswire/ -- Only about half of US employers (52%) say they effectively manage healthcare costs, according to Gallagher's 2024 US Physical & Emotional Wellbein
Novo Nordisk GLP-1 drug shows encouraging signs in early stage Alzheimer's trial
08:46am, Tuesday, 30'th Jul 2024
A small clinical trial revealed that a weight-loss drug from the GLP-1 receptor agonist class slowed brain volume loss in people with mild Alzheimer's disease. The trial results, presented at the Alzh
Older GLP-1 drug from Novo Nordisk may slow Alzheimer's disease progression by protecting the brain, study says
07:00am, Tuesday, 30'th Jul 2024
An older, once-daily drug for diabetes and obesity from Novo Nordisk called liraglutide may slow the progression of Alzheimer's disease by protecting patients' brains, according to data from a mid-sta
Fractyl Health Receives FDA Breakthrough Device Designation for Revita in Weight Maintenance for People with Obesity Who Discontinue GLP-1 Based Drugs
Biohaven: Taldefgrobep Alfa Might Have A Place Beyond SMA Treatment
11:48am, Friday, 26'th Jul 2024
Results from phase 3 RESILIENT study, using taldefgrobep alfa for the treatment of patients with spinal muscular atrophy, expected in the 2nd half of 2024. The global spinal muscular atrophy treatment
Obese and overweight participants receiving bi-weekly doses of 12 mg, 18 mg, 24 mg, 48 mg, and once-weekly dose of 24 mg GZR18 for 30 weeks achieved mean percent changes in body weight from baseline
Hims & Hers Health: Expecting A Healthy Report
10:00am, Sunday, 21'st Jul 2024
Hims & Hers Health has fallen below $20 after initial excitement over a compounded GLP-1 drug solution wanes. The health and wellness platform offers a compounded semaglutide drug at lower prices due
Hims & Hers: The Thesis Goes Far Beyond GLP-1
05:34pm, Thursday, 18'th Jul 2024
Hims & Hers is dedicated to telehealth and provides healthcare services remotely. It has an asset-light business model that has had extraordinary growth. The company began its growth by attacking mark
Positive Interim Body Weight Results from Lexaria's Diabetes Animal Study
10:30am, Wednesday, 17'th Jul 2024
DehydraTECH appears to work with a second GLP-1 drug - liraglutide DehydraTECH appears to be working with semaglutide both with and without SNAC technology DehydraTECH-CBD is showing strong apparent p
Genentech Announces Positive Phase I Results of Its Oral GLP-1 Receptor Agonist CT-996 for the Treatment of People With Obesity
01:10am, Wednesday, 17'th Jul 2024
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline results from two arms of an ongoing multi-part Phase
Dario Expands GLP-1 Solution Client Base with New Employer Contract
08:30am, Tuesday, 16'th Jul 2024
Dario's leading behavior change solutions continue to win interest in the employer, payer and pharmaceutical markets NEW YORK , July 16, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario"
Don't place your hopes on Hims & Hers GLP-1 business, says Jim Cramer
08:09pm, Wednesday, 10'th Jul 2024
'Mad Money' host Jim Cramer takes a look at Hims & Hers to assess if its a good healthcare move for your portfolio.
Better GLP-1 Biotech Stock: Altimmune vs. Viking Therapeutics
06:41am, Wednesday, 10'th Jul 2024
GLP-1 medicines for obesity are all the rage these days. Viking Therapeutics' candidate has the edge in the speed of weight loss.
Dosing is Complete in Lexaria's Second GLP-1 Human Pilot Study
09:10am, Tuesday, 09'th Jul 2024
All three dosing arms have been completed. KELOWNA, BC / ACCESSWIRE / July 9, 2024 / Lexaria Bioscience Corp. (Nasdaq:LEXX & LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery pl
